Incidence of Cardiac Toxicity with Azacitidine
The incidence of cardiac toxicity with azacitidine is rare but clinically significant, with cardiac failure occurring in approximately 1-5% of patients and pericarditis representing an emerging safety signal with statistically significant disproportionality in pharmacovigilance databases.
Cardiac Failure Incidence
The FDA label for azacitidine does not specifically quantify cardiac failure rates in its adverse event tables, though it lists cardiac failure as a recognized adverse reaction 1. Real-world pharmacovigilance data provides more precise estimates:
- A Japanese pharmacovigilance analysis identified cardiac failure as a high-risk adverse event with azacitidine, demonstrating a particularly high mortality rate once it occurs 2
- French case series combined with WHO Vigibase analysis found 307 individual case safety reports of cardiac failure associated with azacitidine, with significant disproportionality signals: reported odds ratio (ROR) of 1.3 for the broad cardiac failure category, ROR of 5.1 for cardiac failure, and ROR of 23.2 for acute cardiac failure 3
The timing is critical: most cardiac adverse events occur within the first month of treatment 2. Patients with pre-existing cardiovascular disease appear at substantially higher risk, as all four patients in the French case series had cardiovascular history 3.
Pericardial Complications Incidence
Pericarditis represents a statistically significant safety signal with azacitidine:
- FDA Adverse Event Database analysis identified 48 reports of azacitidine-induced pericarditis with a proportional reporting ratio of 5.0, reporting odds ratio of 5.0, and information component (IC025) of 1.8—all indicating significant disproportionality 4
- The most common indications in these reports were myelodysplastic syndrome (48%) and acute myeloid leukemia (27%) 4
- A single-center case series reported three cases of pericarditis over 3 years, with onset ranging from during cycle 1 to 3 weeks after completing cycle 5 5
Pericardial effusions can occur as pleuropericardial effusions, as documented in case reports where this manifested as late as the eighth treatment cycle 6.
Clinical Context and Risk Stratification
The cardiac toxicity profile differs substantially from traditional chemotherapy agents. Unlike anthracyclines where cumulative dose-dependent cardiotoxicity is well-established (4-36% with doxorubicin at 500-550 mg/m²) 7, 8, or trastuzumab (2-7% heart failure incidence) 7, azacitidine's cardiac effects appear idiosyncratic rather than dose-dependent.
Key distinguishing features:
- Cardiac events can occur at any cycle, not following a predictable cumulative pattern
- Pre-existing cardiovascular disease substantially amplifies risk
- Symptoms may be non-specific (fatigue, weakness) or classic cardiac presentations (chest pain, dyspnea, edema)
- Both cardiac failure and pericarditis can be reversible with drug discontinuation and appropriate management 3, 5, 6
Monitoring Implications
Given the mortality risk once cardiac failure develops and the potential reversibility with early detection:
- Baseline cardiovascular assessment is essential before initiating azacitidine
- Heightened vigilance during the first month of treatment when most events occur 2
- Any unexplained chest pain, dyspnea, or signs of heart failure warrant immediate cardiac evaluation
- Patients with cardiovascular history require more intensive monitoring, though specific intervals are not established in guidelines
The relatively low absolute incidence (1-5%) should not diminish clinical concern, as the mortality rate after cardiac failure onset is notably high 2, 3, making early recognition and intervention critical for patient outcomes.